Search research articles
Contact Us
Filters
Showing results (341-350 of 397) with videos related to
Page
of 40
Sort By:
Gynecologic Oncology
|
September 12, 2020
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
Danny Rischin, Marta Gil-Martin, Antonio González-Martin, et al.
The Oncologist
|
March 23, 2023
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience
Mirella Nardo, Bulent Yilmaz, Blessie Elizabeth Nelson, et al.
The Lancet. Oncology
|
September 30, 2019
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
Aung Naing, Deborah J Wong, Jeffrey R Infante, et al.
Investigational New Drugs
|
November 22, 2017
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
Takeo Fujii, Rivka R Colen, Mehmet Asim Bilen, et al.
British Journal of Cancer
|
April 27, 2018
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
Shiraj Sen, Shumei Kato, Rishi Agarwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)
Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.
Journal of the National Cancer Institute
|
September 1, 2016
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma
Salah-Eddine Lamhamedi-Cherradi, Brian A Menegaz, Vandhana Ramamoorthy, et al.
Journal of Immunotherapy and Precision Oncology
|
February 8, 2023
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer
Ji Son, Heather Y Lin, Siqing Fu, et al.
Clinical Genitourinary Cancer
|
August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials
Omar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
JCI Insight
|
April 20, 2017
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients
Vivek Subbiah, Muhammad Rizwan Khawaja, David S Hong, et al.
Page
of 40
Search research articles
Search
Showing results (341-350 of 397) with videos related to
Sort By:
Page
of 40
Gynecologic Oncology
|
September 12, 2020
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
Danny Rischin, Marta Gil-Martin, Antonio González-Martin, et al.
The Oncologist
|
March 23, 2023
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience
Mirella Nardo, Bulent Yilmaz, Blessie Elizabeth Nelson, et al.
The Lancet. Oncology
|
September 30, 2019
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
Aung Naing, Deborah J Wong, Jeffrey R Infante, et al.
Investigational New Drugs
|
November 22, 2017
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
Takeo Fujii, Rivka R Colen, Mehmet Asim Bilen, et al.
British Journal of Cancer
|
April 27, 2018
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
Shiraj Sen, Shumei Kato, Rishi Agarwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)
Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.
Journal of the National Cancer Institute
|
September 1, 2016
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma
Salah-Eddine Lamhamedi-Cherradi, Brian A Menegaz, Vandhana Ramamoorthy, et al.
Journal of Immunotherapy and Precision Oncology
|
February 8, 2023
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer
Ji Son, Heather Y Lin, Siqing Fu, et al.
Clinical Genitourinary Cancer
|
August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials
Omar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
JCI Insight
|
April 20, 2017
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients
Vivek Subbiah, Muhammad Rizwan Khawaja, David S Hong, et al.
Page
of 40